Radiofármacos e Radioligantes no Tratamento do Câncer de Próstata

Dalton Alexandre dos Anjos; Marcos Santos

doi:10.66305/jbas.v5i1.33

Radiopharmaceuticals and Radioligand Therapy in the Treatment of Prostate Cancer

Authors

Dalton Alexandre dos Anjos Coordenador de Medicina Nuclear da DASA em São Paulo
Marcos Santos Médico-Radiologista

DOI:

https://doi.org/10.66305/jbas.v5i1.33

Keywords:

Radiopharmaceuticals, Radioligand, Prostate cancer

Abstract

The study addresses the management of metastatic castration-resistant prostate cancer (mCRPC) using a range of therapeutic approaches, including systemic therapies, chemotherapy, PARP inhibitors for patients with BRCA1/2 mutations, and radiopharmaceuticals.

Author Biography

Dalton Alexandre dos Anjos, Coordenador de Medicina Nuclear da DASA em São Paulo

Diretor de Defesa Profissional e Ética da Sociedade Brasileira de Medicina Nuclear

Downloads

PDF (Português (Brasil))

Published

2026-02-06

How to Cite

Alexandre dos Anjos, D., & Santos, M. (2026). Radiopharmaceuticals and Radioligand Therapy in the Treatment of Prostate Cancer. Brazilian Journal of Health Auditing, 5(1), 16–32. https://doi.org/10.66305/jbas.v5i1.33